Drug Trial Radar · NCT07223697
A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Jan 8, 2026
Primary completion
Mar 1, 2033
Study completion Mar 1, 2033
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Nov 3, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess long-term safety and efficacy of Afimkibart (also known as RO7790121) in participants with Atopic Dermatitis (AD) who participated in previous afimkibart clinical trials.
Conditions
- Atopic Dermatitis
Interventions
AfimkibartDrug
Afimkibart SC injection will be administered as per the schedule defined in the protocol.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants with Adverse EventsTime frame: From Baseline up to 6 years
Locations
31 sites in 7 countries. Site status is shown where the registry gives one.
UCLA Division of Dermatology
Los Angeles, California
Dermatology Research Associate
Los Angeles, California
Olympian Clinical Research
Tampa, Florida
Hamilton Research, LLC
Alpharetta, Georgia
Revival Research Institute, LLC
Troy, Michigan
University of Minnesota
Minneapolis, Minnesota
Best Skin Research LLC
Camp Hill, Pennsylvania
Instituto Brasil de Pesquisa Clínica-IBPCLIN S/A
Rio de Janeiro, Brazil
Centro de Estudos em Terapias Inovadoras ? CETI
Curitiba, Paraná, Brazil
Irmandade Da Santa Casa de Misericordia de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil
Hospital de Clnicas de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil
UNESP - Faculdade de Medicina da Universidade Estadual Paulista - Campus Botucatu
Botucatu, São Paulo, Brazil
Centro de Pesquisa São Lucas
Campinas, São Paulo, Brazil
HMCG - Hospital e Maternidade Dr. Christovo da Gama
Santo Andr, São Paulo, Brazil
Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto Hospital de Base - PPDS
Sao Jose Rio Preto, São Paulo, Brazil
DermEffects
London, Ontario, Canada
Lynderm Research Inc
Markham, Ontario, Canada
DermEdge Research
Mississauga, Ontario, Canada
Ryan Clinical Research Inc
Newmarket, Ontario, Canada
Dermatologikum Hamburg Gemeinschaftspraxis GbR
Hamburg, Germany
Fachklinik Bad Bentheim
Bad Bentheim, Lower Saxony, Germany
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Rome, Lazio, Italy
Azienda Ospedaliero Universitaria delle Marche
Ancona, The Marches, Italy
Centrum Medyczne Pratia Gdynia
Gdynia, Poland
Specjalistyczny Gabinet Dermatologiczny Aplikacyjno-Badawczy Marek Brzewski, Pawel Brzewski s.c.
Krakow, Poland
Centrum Nowoczesnych Terapii "Dobry Lekarz"
Krakow, Poland
Uniwersytecki Szpital Kliniczny im.Fryderyka Chopina w Rzeszowie
Rzeszów, Poland
Klinika Ambroziak Dermatologia
Warsaw, Poland
Centrum Medyczne Pratia Katowice I
Katowice, Silesian Voivodeship, Poland
Hospital Universitario Reina Sofia
Córdoba, Spain
Clinica Universidad de Navarra
Pamplona, Navarre, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.